ATE498633T1 - Materialien und verfahren zur stimulierung des immunsystems - Google Patents

Materialien und verfahren zur stimulierung des immunsystems

Info

Publication number
ATE498633T1
ATE498633T1 AT05770983T AT05770983T ATE498633T1 AT E498633 T1 ATE498633 T1 AT E498633T1 AT 05770983 T AT05770983 T AT 05770983T AT 05770983 T AT05770983 T AT 05770983T AT E498633 T1 ATE498633 T1 AT E498633T1
Authority
AT
Austria
Prior art keywords
immune response
compound
methods
antigen
stimulating
Prior art date
Application number
AT05770983T
Other languages
English (en)
Inventor
P K Raveendran Nair
Steven Melnick
Cheppail Ramachandran
Original Assignee
Variety Children S Hospital D B A Miami Children S Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variety Children S Hospital D B A Miami Children S Hospital filed Critical Variety Children S Hospital D B A Miami Children S Hospital
Application granted granted Critical
Publication of ATE498633T1 publication Critical patent/ATE498633T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05770983T 2004-07-09 2005-07-11 Materialien und verfahren zur stimulierung des immunsystems ATE498633T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58654804P 2004-07-09 2004-07-09
PCT/US2005/024410 WO2006010069A1 (en) 2004-07-09 2005-07-11 Materials and methods for immune system stimulation

Publications (1)

Publication Number Publication Date
ATE498633T1 true ATE498633T1 (de) 2011-03-15

Family

ID=34973215

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770983T ATE498633T1 (de) 2004-07-09 2005-07-11 Materialien und verfahren zur stimulierung des immunsystems

Country Status (8)

Country Link
US (1) US7425548B2 (de)
EP (1) EP1781708B1 (de)
JP (1) JP5165372B2 (de)
AT (1) ATE498633T1 (de)
DE (1) DE602005026407D1 (de)
ES (1) ES2360862T3 (de)
IL (1) IL180612A (de)
WO (1) WO2006010069A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652546B2 (en) * 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
RU2348417C1 (ru) * 2007-03-30 2009-03-10 Ирина Николаевна Зуева Способ коррекции нейроэндокринного и иммунного состояния организма (варианты)
US8008031B2 (en) * 2007-12-19 2011-08-30 National Pingtung University Of Science And Technology Competitive receptor binding assay for detecting beta-glucans
CN102138075B (zh) * 2008-10-01 2014-05-28 三星电子株式会社 离心式微流体设备、制造微流体设备的方法以及使用微流体设备测试样品的方法
FI20080665A0 (fi) * 2008-12-18 2008-12-18 Glykos Finland Oy Luonnollisen tyyppiset sakkaridikoostumukset
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
MY179036A (en) * 2012-12-13 2020-10-26 Malaysian Palm Oil Board Anti-proliferative effects of palm vegetation liquor and extracts thereof in preventing pancreatic cancer
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
KR101629656B1 (ko) * 2014-10-24 2016-06-14 충남대학교산학협력단 면역증강효과를 갖는 수용성 다당체 및 이를 함유하는 조성물
CA2994076A1 (en) 2018-02-06 2019-08-06 Brand Shared Services Llc Formwork system
CN112566650A (zh) * 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途
CN110437343A (zh) * 2019-07-16 2019-11-12 江苏农牧科技职业学院 一种香菇多糖的提取方式

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166379A (en) * 1990-02-16 1992-11-24 Harbor Branch Oceanographic Institution, Inc. Synthesis of compounds with biological activity, and methods of use
IN184422B (de) 1993-06-01 2000-08-26 Council Scient Ind Res
IN183192B (de) 1994-01-25 1999-10-02 Council Scient Ind Res
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
IN179810B (de) 1996-06-20 1997-12-13 Raptakos Brett & Co Ltd
US5683698A (en) * 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
IN183487B (de) 1997-07-15 2000-01-15 Synit Drugs Pvt Ltd
IN183805B (de) 1998-01-29 2000-04-22 Bhabha Atomic Res Ct
US6451354B1 (en) * 1999-10-26 2002-09-17 Pharma Terra, Inc. Natural product composition for decreasing IgE production and treating secondary allergic responses
EP1345615A1 (de) * 2000-12-28 2003-09-24 Noel John De Souza Verwendung von tinospora-extrakt bei der behandlung von immunsystem-modulierten störungen
US20040033273A1 (en) * 2001-02-14 2004-02-19 Ayurcore, Inc. Withasol and methods of use
US6379721B1 (en) * 2001-02-15 2002-04-30 Council For Scientific And Industrial Research Process for preparation of α-amylase from Tinospora cordifolia Miers useful for starch saccharification
GB0116948D0 (en) * 2001-07-11 2001-09-05 Sahajanand Biotech Private Ltd Herbal formulation
US6582733B1 (en) * 2002-05-15 2003-06-24 Som C. Pruthi Composition for the treatment of hepatitis including HCV

Also Published As

Publication number Publication date
WO2006010069A1 (en) 2006-01-26
IL180612A0 (en) 2007-06-03
EP1781708A1 (de) 2007-05-09
JP2008506024A (ja) 2008-02-28
DE602005026407D1 (de) 2011-03-31
US20060009501A1 (en) 2006-01-12
US7425548B2 (en) 2008-09-16
EP1781708B1 (de) 2011-02-16
IL180612A (en) 2013-04-30
ES2360862T3 (es) 2011-06-09
JP5165372B2 (ja) 2013-03-21

Similar Documents

Publication Publication Date Title
IL180612A0 (en) Materials and methods for immune system stimulation
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
IL178877A0 (en) Activatable particles, preparations and uses
EP2292264A3 (de) Methoden und Zusammensetzungen zur Erhöhung der Wirksamkeit von therapeutischen Antikörper unter Verwendung von Verbindungen, die NK-Zellen potenzieren
BRPI0518281A2 (pt) inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
EP4331604A3 (de) Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zellfunktion
HUE038833T2 (hu) Antigénspecifikus T-sejtek létrehozása
BRPI0622298A8 (pt) Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
DK1778680T3 (da) Spirocykliske cyclohexaderivater
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
EP1556513A4 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
AR039186A1 (es) Celulas madre indiferenciadas programables de origen monocitaro, su obtencion y uso
SI1730147T1 (sl) Substituirane triazaspiro dekan onskespojine za zdravljenje obezitete
WO2004027036A3 (en) Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
TW200509863A (en) Irradiation device for medical use
BR0015597A (pt) Uso de anticorpos como vacinas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties